Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC. (Q55279827)
Jump to navigation
Jump to search
scientific article published on 6 November 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC. |
scientific article published on 6 November 2014 |
Statements
1 reference
Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC. (English)
1 reference
Bernard Fox
1 reference
Traci Hilton
1 reference
Rachel Sanborn
1 reference
Brian Boulmay
1 reference
Rui Li
1 reference
Bradley Spieler
1 reference
Kyle Happel
1 reference
Christopher Paustian
1 reference
Tarsem Moudgil
1 reference
Christopher Dubay
1 reference
Brenda Fisher
1 reference
Eileen Mederos
1 reference
Augusto Ochoa
1 reference
Walter J Urba
1 reference
Hong-Ming Hu
1 reference
6 November 2014
1 reference
2
1 reference
Suppl 3
1 reference
P249-P249
1 reference
Identifiers
1 reference